Engineering Immune Cells to Fight Gut Senescence

Published on December 4, 2025

Recent research published in Nature Aging presents groundbreaking findings on utilizing CAR T cells to combat senescence in the intestinal epithelium, a critical factor in maintaining gut health as we age.

Introduction

Aging negatively impacts the body in various ways, particularly in how quickly certain tissues regenerate. The intestinal epithelium, responsible for lining the gut, is one of the fastest to replace its cells. Unfortunately, this regenerative ability diminishes with age, resulting in what is known as "leaky gut," which can lead to further complications such as inflammation and chronic conditions.

Understanding Gut Senescence

Research focuses on two significant hallmarks of aging relevant to gut health:

  • Inflammaging: This term describes the chronic, age-related inflammation that presents a significant risk to health.
  • Senescent Cells: These are cells that have entered a state of permanent growth arrest, contributing to aging and disease as they accumulate over time.

Mechanism of Action

In their study, the researchers investigated uPAR (urinary plasminogen activator receptor) cells, which are known to be harmful in their excess. Previous studies indicated that CAR T cells programmed to attack these receptors could mitigate some senescence-related issues. For instance, CAR T cells have shown promise in combating liver fibrosis.

Methodology

The research team analyzed intestinal samples from both young (3-month-old) and older (20-month-old) mice:

Age Group uPAR Cells SA-β-gal Expression
3 Months Normal Levels Low
20 Months Increased Levels High

This analysis showcased that older mice had a significant increase in both uPAR-expressing cells and senescence markers, leading to a decline in gut functionality.

Results

After administering CAR T cells targeting uPAR into the bloodstreams of the mice, notable results were recorded:

  • Reduction in Senescent Cells: The numbers of uPAR and SA-β-gal cells declined dramatically in older mice.
  • Restored Gut Integrity: Improved intestinal permeability was observed through FITC-Dextran analysis.
  • Enhanced Stem Cell Activity: The proliferating stem cells in treated mice showed increased capability to develop organoids.
  • Microbiome Improvements: The gut flora composition in treated animals began to resemble that of younger cohorts, indicating better gut health.

Long-Term Benefits

Remarkably, a single treatment with anti-uPAR CAR T cells in young mice had long-lasting effects. The benefits were evident up to 15 months later, with a persistent reduction in cellular senescence and improvements in gut health indicators.

Comparison with Existing Treatments

The study also examined the known senolytic combination of dasatinib and quercetin:

Treatment Outcome
Anti-uPAR CAR T Cells Significant reduction in senescent cells and improved gut health.
Dasatinib + Quercetin Similar effects on senescent cells and gut integrity.

Conclusion

Overall, the researchers have determined that uPAR+ epithelial cells play a crucial role in driving gut aging and related inflammation. Although this approach had potential cancer concerns, no intestinal cancers were observed in treated mice, signaling a promising avenue for human trials.

The search for effective treatments to address aging-related decline continues, with clinical trials anticipated to ascertain the safety and efficacy of this CAR T cell therapy in humans.

Literature References

[1] Barker, N. (2014). Adult intestinal stem cells: critical drivers of epithelial homeostasis and regeneration. Nature Reviews Molecular Cell Biology, 15(1), 19-33.

[2] Brunet, A., Goodell, M. A., & Rando, T. A. (2023). Ageing and rejuvenation of tissue stem cells and their niches. Nature Reviews Molecular Cell Biology, 24(1), 45-62.

[3] Dumic, I., et al. (2019). Gastrointestinal tract disorders in older age. Canadian Journal of Gastroenterology and Hepatology, 2019(1), 6757524.

[4] Amor, C., et al. (2020). Senolytic CAR T cells reverse senescence-associated pathologies. Nature, 583(7814), 127-132.

[5] Dai, H., et al. (2024). Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models. Journal of Hepatology, 80(6), 913-927.

[6] Saul, D., et al. (2022). A new gene set identifies senescent cells and predicts senescence-associated pathways across tissues. Nature Communications, 13(1), 4827.